Improved Mobilization of Exogenous Mesenchymal Stem Cells to Bone for Fracture Healing and Sex Difference
Open Access
- 15 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 34 (10) , 2587-2600
Abstract
Mesenchymal stem cell (MSC) transplantation has been tested in animal and clinical fracture studies. We have developed a bone-seeking compound, LLP2A-Alendronate (LLP2A-Ale) that augments MSC homing to bone. The purpose of this study was to determine whether treatment with LLP2A-Ale or a combination of LLP2A-Ale and MSCs would accelerate bone healing in a mouse closed fracture model and if the effects are sex dependent. A right mid-femur fracture was induced in two-month-old osterix-mCherry (Osx-mCherry) male and female reporter mice. The mice were subsequently treated with placebo, LLP2A-Ale (500 μg/kg, IV), MSCs derived from wild-type female Osx-mCherry adipose tissue (ADSC, 3 x 105, IV) or ADSC + LLP2A-Ale.In phosphate buffered saline-treated mice, females had higher systemic and surface-based bone formation than males. However, male mice formed a larger callus and had higher volumetric bone mineral density and bone strength than females. LLP2A-Ale treatment increased exogenous MSC homing to the fracture gaps, enhanced incorporation of these cells into callus formation, and stimulated endochondral bone formation. Additionally, higher engraftment of exogenous MSCs in fracture gaps seemed to contribute to overall fracture healing and improved bone strength. These effects were sex-independent.There was a sex-difference in the rate of fracture healing. ADSC and LLP2A-Ale combination treatment was superior to on callus formation, which was independent of sex. Increased mobilization of exogenous MSCs to fracture sites accelerated endochondral bone formation and enhanced bone tissue regeneration.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR061366)
- California Institute for Regenerative Medicine (DR2A-05302)
This publication has 93 references indexed in Scilit:
- Reversing bone loss by directing mesenchymal stem cells to boneStem Cells, 2013
- In Vivo Fate Mapping Identifies Mesenchymal Progenitor CellsStem Cells, 2012
- Mesenchymal Stem Cells Expressing Insulin-like Growth Factor-I (MSCIGF) Promote Fracture Healing and Restore New Bone Formation in Irs1 Knockout Mice: Analyses of MSCIGF Autocrine and Paracrine Regenerative EffectsStem Cells, 2011
- Human Gingiva-Derived Mesenchymal Stem Cells Elicit Polarization of M2 Macrophages and Enhance Cutaneous Wound HealingStem Cells, 2010
- Regenerative Effects of Transplanted Mesenchymal Stem Cells in Fracture HealingStem Cells, 2009
- Glucocorticoid‐induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralizationArthritis & Rheumatism, 2008
- Teriparatide (1‐34 human PTH) regulation of osterix during fracture repairJournal of Cellular Biochemistry, 2008
- Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up studyInternational Orthopaedics, 2008
- IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host diseaseEuropean Journal of Immunology, 2008
- Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusionInternational Orthopaedics, 2007